Evaluation of NBF Gingival Gel for treatment of inflammation in gums after cleaning of teeth by doctor and the effect on levels of anti-oxidants in saliva after using this gel.

â??Clinical Evaluation of NBF gel as an adjunct to scaling and its effect on the Total Anti-oxidant capacity of saliva in Gingivitis patientsâ??

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/01/011162

Enrollment

Registered

2018-01-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Chronic Marginal Gingivitis

Interventions

Intervention1: NBF Gingival gel: NBF gel combines the advantages of Nano-technology and anti-oxidants. it acts as an adjunct to scaling and root planing. Control Intervention1: Scaling and NBF gingiva

Eligibility

Inclusion criteria

Inclusion criteria: Age group between 20-60 years. 2. Patients in good systemic health. 3. Patients classified as stage II and stage III gingivitis based upon the gingival score given by Loe and Silness 1964. 4. Patients with minimum of 20 teeth. 5. Patients who had not received any type of periodontal therapy for the past 1 year.

Exclusion criteria

Exclusion criteria: 1. Patients suffering from any systemic diseases or with compromised immune system. 2. Patients with a known history of drug allergy 3. Patients taking any drug known to cause gingival enlargement 4. Patients taking any immuno-suppressive drugs like corticosteroids. 5. Grade II and Grade III mobile teeth, 6. Pregnant and/or lactating mothers. 7. Patients with any bleeding disorders. 8. Patient on anticoagulant therapy.

Design outcomes

Primary

Measure	Time frame
1. Gingival index (Loe and Silness-1964) 2. Papilla bleeding index (Muhlemann-1977) 3. Total Antioxidant capacity of SalivaTimepoint: 1. Gingival index (Loe and Silness-1964) recorded at baseline and 1 month post treatment. 2. Papilla bleeding index (Muhlemann-1977)recorded at baseline and 1 month post treatment. 3. Total Antioxidant capacity of Saliva recorded at baseline and 1 month post treatment.	—

Measure

Time frame

1. Gingival index (Loe and Silness-1964) 2. Papilla bleeding index (Muhlemann-1977) 3. Total Antioxidant capacity of SalivaTimepoint: 1. Gingival index (Loe and Silness-1964) recorded at baseline and 1 month post treatment. 2. Papilla bleeding index (Muhlemann-1977)recorded at baseline and 1 month post treatment. 3. Total Antioxidant capacity of Saliva recorded at baseline and 1 month post treatment.

—

Secondary

Measure	Time frame
Total Antioxidant capacity of SalivaTimepoint: Total Antioxidant capacity of Saliva will be evaluated at baseline and 1 month after scaling.	—

Countries

India

Contacts

Public ContactDr Abhinav Deshpande

Nair Hospital Dental College

maladixit25@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026